<!DOCTYPE html>
    <html lang="en">
    
    <head>
        <meta charset="UTF-8">
        <meta http-equiv="X-UA-Compatible" content="IE=edge">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">
        <script async src="https://www.googletagmanager.com/gtag/js?id=G-PQPWWZGD1B"></script>
        <script>
        window.dataLayer = window.dataLayer || [];
        function gtag(){dataLayer.push(arguments);}
        gtag('js', new Date());

        gtag('config', 'G-PQPWWZGD1B');
        </script>
<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-7833742603914548"
     crossorigin="anonymous"></script>
        <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/katex@0.16.0/dist/katex.min.css" integrity="sha384-Xi8rHCmBmhbuyyhbI88391ZKP2dmfnOl4rT9ZfRI7mLTdk1wblIUnrIq35nqwEvC" crossorigin="anonymous">
        <link rel="stylesheet" href="/assets/css/min/@ui.css">
        <link rel="shortcut icon" href="/assets/images/favicons/favicon.ico">
        <link rel="apple-touch-icon-precomposed" href="/assets/images/favicons/apple-touch-icon-152x152-precomposed.png">
        <link rel="apple-touch-icon" sizes="180x180" href="/assets/images/favicons/apple-touch-icon.png">
        <link rel="icon" type="image/png" sizes="32x32" href="/assets/images/favicons/favicon-32x32.png">
        <link rel="icon" type="image/png" sizes="16x16" href="/assets/images/favicons/favicon-16x16.png">
        <link rel="manifest" href="/assets/images/favicons/site.webmanifest">
        <link rel="mask-icon" href="/assets/images/favicons/safari-pinned-tab.svg" color="#10106d">
        <meta name="msapplication-TileColor" content="#10106d">
        <meta name="msapplication-config" content="/assets/images/favicons/browserconfig.xml">
        <meta name="theme-color" content="#10106d">
        <link rel="canonical" href="https://vlavar.com/engineeringdb/transdermal-drug-delivery-involves-the-controlled-time-release-of-medication-through-the-skin-to-the-bloodstream-usually-from-a-patch-that-is-adhered-to-the-body-advantages-include-steady-and-mild-d" />
        <meta property="og:locale" content="en_US" />
        <meta property="og:type" content="article" />
        <meta property="og:site_name" content="Vlavar" />
        <meta property="article:publisher" content="admin@vlavar" />
       <title>Transdermal drug delivery involves the controlled time-release of medication through the skin to the bloodstream, usually from a patch that is adhered to the body. Advantages include steady and mild drug delivery rates that reduce shock to the system as might occur with intravenous infusions, the [solved] | Vlavar Engineering</title>
<meta property="og:title" content="Transdermal drug delivery involves the controlled time-release of medication through the skin to the bloodstream, usually from a patch that is adhered to the body. Advantages include steady and mild drug delivery rates that reduce shock to the system as might occur with intravenous infusions, the[solved!] | Vlavar Engineering" />
<meta name="description" content="Known: Initial density of a drug within a transdermal patch, size of the patch, partition coefficient, and mass diffusivities. Find: Total dosage of medicine"/>
<meta property="og:description" content="Known: Initial density of a drug within a transdermal patch, size of the patch, partition coefficient, and mass diffusivities. Find: Total dosage of medicine" />

<meta property="og:updated_time" content="2022-07-18T08:12:14+04:00" />
<meta name="twitter:description" content="Known: Initial density of a drug within a transdermal patch, size of the patch, partition coefficient, and mass diffusivities. Find: Total dosage of medicine" />
<meta name="twitter:title" content="Transdermal drug delivery involves the controlled time-release of medication through the skin to the bloodstream, usually from a patch that is adhered to the body. Advantages include steady and mild drug delivery rates that reduce shock to the system as might occur with intravenous infusions, the[solved!] | Vlavar Engineering" />

<meta property="article:published_time" content="2022-07-15T14:28:34+04:00" />
        <meta property="og:url" content="https://vlavar.com/engineeringdb/transdermal-drug-delivery-involves-the-controlled-time-release-of-medication-through-the-skin-to-the-bloodstream-usually-from-a-patch-that-is-adhered-to-the-body-advantages-include-steady-and-mild-d" />
        <meta property="article:author" content="admin@vlavar" />
        <meta name="twitter:card" content="summary_large_image" />
        <meta name="twitter:site" content="admin@vlavar" />
        <meta name="twitter:creator" content="admin@vlavar" />
     
    </head>
    
    <body>
        <nav id="desktop" class="desktop">
            <div id="desktop-container" class="container">
                <h1 id="logo"><a href="/">Vlavar</a></h1>
                <div id="desktop-menu" class="menu">
                    <a href="/">Home</a>
                    <a id="search">Search</a>
                    <a href="/tour/1">Tour</a>
                    <a href="/contact-us">Contact Us</a>
                </div>
                <button id="burger-button" class="hamburger">
                    <span></span>
                    <span></span>
                    <span></span>
                </button>
    
            </div>
        </nav>
        <nav id="mobile-navbar" class="mobile-nav">
            <div class="one text-fade"><a class="nav-link" href="/">Home</a></div>
            <div class="two text-fade"><a class="nav-link" id="search-mobile">Search</a></div>
            <div class="three text-fade"><a class="nav-link" href="/tour/1">Tour</a></div>
            <div class="four text-fade"><a class="nav-link" href="/contact-us">COntact Us</a></div>
        </nav>
    
        <div id="container" class="container-items tour">
            <div id="searchbox" class="searchbox">
                <div class="search">
                    <div class="icon"></div>
                    <form class="form">
                        <div class="input">
                        <input type="text" id="x" placeholder="Find solutions to engineering problems " autocomplete="off" >

                        </div>
                    </form>
                </div>
            </div>
            <div class="items question-block"> <span class="question">Guest Question. </span>
            <p class="blog">Transdermal drug delivery involves the controlled time-release of medication through the skin to the bloodstream, usually from a patch that is adhered to the body. Advantages include steady and mild drug delivery rates that reduce shock to the system as might occur with intravenous infusions, the ability to deliver medication to nauseated or unconscious patients that would be otherwise delivered in oral form, and ease of use. Consider a square patch of length and width L = 50 mm that consists of a host medium containing an initial, uniform density of medication, <span class="tex-text">\(\rho_{ A , p, i}=100 kg / m ^{3}\)</span>. The patch is applied to the skin, which contains an initial drug concentration of <span class="tex-text">\(\rho_{ A , s, i}=0.\)</span> At the patch–skin interface located at x = 0, the ratio of the medication density on the patch side to the medication density on the patient side is described by a partition coefficient of K = 0.5.</p> <p class="blog">1. Determine the total amount of medication (dosage) delivered to the patient over a treatment period of one week. Nominal values of the diffusion coefficients of the medication within the patch and skin are <span class="tex-text">\(D_{ A p}=0.1 \times 10^{-12} m ^{2} / s \text { and } D_{ A s}=0.2 \times 10^{-12} m ^{2} / s\)</span>, respectively.</p> <p class="blog">2. Investigate the sensitivity of the total dosage delivered to the patient to the mass diffusivity of the patch, <span class="tex-text">\(D_{ A p},\)</span> and the mass diffusivity of the patient’s skin, <span class="tex-text">\(D_{ A s}.\)</span></p>      
    <!-- end -->
            </div>
    
            <div class="items blog-solution">
                <div class="admin"><span>Admin</span> <svg class="verified-badge" xmlns="http://www.w3.org/2000/svg"
                        version="1.1" viewBox="0,0,24,24">
                        <path
                            d="M22.5 12.5c0-1.58-.875-2.95-2.148-3.6.154-.435.238-.905.238-1.4 0-2.21-1.71-3.998-3.818-3.998-.47 0-.92.084-1.336.25C14.818 2.415 13.51 1.5 12 1.5s-2.816.917-3.437 2.25c-.415-.165-.866-.25-1.336-.25-2.11 0-3.818 1.79-3.818 4 0 .494.083.964.237 1.4-1.272.65-2.147 2.018-2.147 3.6 0 1.495.782 2.798 1.942 3.486-.02.17-.032.34-.032.514 0 2.21 1.708 4 3.818 4 .47 0 .92-.086 1.335-.25.62 1.334 1.926 2.25 3.437 2.25 1.512 0 2.818-.916 3.437-2.25.415.163.865.248 1.336.248 2.11 0 3.818-1.79 3.818-4 0-.174-.012-.344-.033-.513 1.158-.687 1.943-1.99 1.943-3.484zm-6.616-3.334l-4.334 6.5c-.145.217-.382.334-.625.334-.143 0-.288-.04-.416-.126l-.115-.094-2.415-2.415c-.293-.293-.293-.768 0-1.06s.768-.294 1.06 0l1.77 1.767 3.825-5.74c.23-.345.696-.436 1.04-.207.346.23.44.696.21 1.04z"
                            fill="#1da1f2" />
                    </svg> </div>
    
                <div class="solution">Solution</div>
    
            </div>
    
            <div class="items answer-block">
                <p class="blog">
<strong>Known:</strong> Initial density of a drug within a transdermal patch, size of the patch, partition coefficient, and mass diffusivities.</p>
 <p class="blog">
<strong>Find:</strong> Total dosage of medicine delivered to the patient over a one-week time period, sensitivity of the dosage to the mass diffusivity of the patch and skin.</p>
 <p class="blog">
<strong>Assumptions:</strong><br /> 1. One-dimensional conditions with constant properties.<br /> 2. Semi-infinite patch and skin.<br /> 3. No chemical reactions.<br /> 4. Stationary media.</p>
 <p class="blog">
<strong>Analysis:</strong><br /> 1. The conservation of species equation applies to both the patch and skin. With the foregoing assumptions, Equation 14.47b becomes</p>
 <p class="blog">
&nbsp;</p>
 <p class="blog">
<span class="tex-text">\(\frac{\partial^{2} \rho_{ A }}{\partial x^{2}}+\frac{\partial^{2} \rho_{ A }}{\partial y^{2}}+\frac{\partial^{2} \rho_{ A }}{\partial z^{2}}+\frac{\dot{n}_{ A }}{D_{ AB }}=\frac{1}{D_{ AB }} \frac{\partial \rho_{ A }}{\partial t}\)</span> (14.47b)</p>
 <p class="blog">
&nbsp;</p>
 <span class="tex-text">\(\frac{\partial^{2} \rho_{ A }}{\partial x^{2}}=\frac{1}{D_{ AB }} \frac{\partial \rho_{ A }}{\partial t}\)</span> <p class="blog">
&nbsp;</p>
 <p class="blog">
which is analogous to Equation 5.29. Moreover, the initial conditions</p>
 <p class="blog">
&nbsp;</p>
 <p class="blog">
<span class="tex-text">\(\frac{\partial^{2} T}{\partial x^{2}}=\frac{1}{\alpha} \frac{\partial T}{\partial t}\)</span> (5.29)</p>
 <p class="blog">
&nbsp;</p>
 <span class="tex-text">\(\rho_{ A }(x&lt;0, t=0)=\rho_{ A , p, i} ; \quad \rho_{ A }(x&gt;0, t=0)=\rho_{ A , s, i}\)</span> <p class="blog">
&nbsp;</p>
 <p class="blog">
boundary conditions</p>
 <p class="blog">
&nbsp;</p>
 <p class="blog">
<span class="tex-text">\(\rho_{ A , p}(x \rightarrow-\infty)=\rho_{ A , p, i} ; \quad \rho_{ A , s}(x \rightarrow+\infty)=\rho_{ A , s, i}\)</span> (1a)</p>
 <p class="blog">
&nbsp;</p>
 <p class="blog">
and interface condition</p>
 <p class="blog">
&nbsp;</p>
 <p class="blog">
<span class="tex-text">\(n_{ A , x, p}^{\prime \prime}(x=0)=n_{ A , x, s}^{\prime \prime}(x=0)\)</span> (1b)</p>
 <p class="blog">
&nbsp;</p>
 <p class="blog">
are analogous to the situation in Figure 5.9 and Equation 5.64 where two semi-infinite solids are brought into thermal contact. In this problem, the partitioning of the species must also be accounted for. That is,</p>
 <p class="blog">
&nbsp;</p>
 <p class="blog">
<span class="tex-text">\(q_{s, A }^{\prime \prime}=q_{s, B }^{\prime \prime}\)</span> (5.64)</p>
 <p class="blog">
&nbsp;</p>
 <p class="blog">
<span class="tex-text">\(\rho_{ A , s}(x=0)=K \rho_{ A , p}(x=0)\)</span> (1c)</p>
 <p class="blog">
&nbsp;</p>
 <p class="blog">
By analogy to Equation 5.65, we have</p>
 <p class="blog">
&nbsp;</p>
 <p class="blog">
<span class="tex-text">\(\frac{-k_{ A }\left(T_{s}-T_{ A , i}\right)}{\left(\pi \alpha_{ A } t\right)^{1 / 2}}=\frac{k_{ B }\left(T_{s}-T_{ B , i}\right)}{\left(\pi \alpha_{ B } t\right)^{1 / 2}}\)</span> (5.65)</p>
 <p class="blog">
&nbsp;</p>
 <span class="tex-text">\(\frac{-D_{ Ap }\left[\rho_{ A , p}(x=0)-\rho_{ A , p, i}\right]}{\sqrt{\pi D_{ A p} t}}=\frac{D_{ As }\left[\rho_{ A , s}(x=0)-\rho_{ A , s, i}\right]}{\sqrt{\pi D_{ As } t}}\)</span> <p class="blog">
&nbsp;</p>
 <p class="blog">
which, after substituting Equation 1c and noting that <span class="tex-text">\(\rho_{ A , s, i}=0,\)</span> may be solved to yield</p>
 <p class="blog">
&nbsp;</p>
 <p class="blog">
<span class="tex-text">\(\rho_{ A , s}(x=0)=\rho_{ A , p, i}\left(\frac{\sqrt{D_{ A p}}}{\sqrt{D_{ As }}+\sqrt{D_{ A p}} / K}\right)\)</span> (2)</p>
 <p class="blog">
&nbsp;</p>
 <p class="blog">
The instantaneous flux of medication to the patient may be determined by noting the analogy with Equation 5.61:</p>
 <p class="blog">
&nbsp;</p>
 <p class="blog">
<span class="tex-text">\(q_{s}^{\prime \prime}(t)=\frac{k\left(T_{s}-T_{i}\right)}{\sqrt{\pi \alpha t}}\)</span> (5.61)</p>
 <p class="blog">
&nbsp;</p>
 <p class="blog">
<span class="tex-text">\(n_{ A }^{\prime \prime}(x=0, t)=\frac{D_{ As } \rho_{ A , s}(x=0)}{\sqrt{\pi D_{ A s} t}}\)</span> (3)</p>
 <p class="blog">
&nbsp;</p>
 <p class="blog">
Substituting Equation 2 into Equation 3 yields</p>
 <p class="blog">
&nbsp;</p>
 <span class="tex-text">\(n_{ A }^{\prime \prime}(x=0, t)=\frac{\rho_{ A , p, i}}{\sqrt{\pi t}} \frac{\sqrt{D_{ A S} D_{ A p}}}{\sqrt{D_{ As }}+\sqrt{D_{ Ap }} / K}\)</span> <p class="blog">
&nbsp;</p>
 <p class="blog">
The dosage, D, delivered to the patient from t = 0 to a treatment time of <span class="tex-text">\(t_{t}\)</span> may be expressed as</p>
 <p class="blog">
&nbsp;</p>
 <span class="tex-text">\(D=L^{2} \int_{t=0}^{t_{t}} n_{ A }^{\prime \prime}(x=0, t) d t\)</span> <p class="blog">
&nbsp;</p>
 <span class="tex-text">\(D=\frac{\rho_{ A , p, i} L^{2}}{\sqrt{\pi}} \frac{\sqrt{D_{ As } D_{ A p}}}{\sqrt{D_{ A s}}+\sqrt{D_{ A p}} / K} \int_{t=0}^{t_{t}} t^{-1 / 2} d t\)</span> <p class="blog">
&nbsp;</p>
 <p class="blog">
<span class="tex-text">\(=\frac{2 \rho_{ A , p, i} L^{2}}{\sqrt{\pi}} \frac{\sqrt{D_{ As } D_{ A p}}}{\sqrt{D_{ A s}}+\sqrt{D_{ A p}} / K} \sqrt{t_{t}}\)</span> (4)</p>
 <p class="blog">
&nbsp;</p>
 <p class="blog">
For a total treatment time of <span class="tex-text">\(t_{t}=7 \text { days } \times 24 h / \text { day } \times 3600 s / h =605 \times 10^{3} s,\)</span> the dosage is</p>
 <p class="blog">
&nbsp;</p>
 <span class="tex-text">\(D=\frac{2 \times 100 kg / m ^{3} \times\left(50 \times 10^{-3} m \right)^{2}}{\sqrt{\pi}}\)</span> <p class="blog">
&nbsp;</p>
 <span class="tex-text">\(\times \frac{\sqrt{0.2 \times 10^{-12} m ^{2} / s \times 0.1 \times 10^{-12} m ^{2} / s }}{\sqrt{0.2 \times 10^{-12} m ^{2} / s }+\sqrt{0.1 \times 10^{-12} m ^{2} / s } / 0.5} \sqrt{605 \times 10^{3} s }\)</span> <p class="blog">
&nbsp;</p>
 <span class="tex-text">\(=29 \times 10^{-6} kg =29 mg\)</span> <p class="blog">
&nbsp;</p>
 <p class="blog">
2. The sensitivity of the dosage to the patch and skin mass diffusivities may be evaluated by solving Equation 4 for different combinations of <span class="tex-text">\(D_{ A p} \text { and } D_{ As }.\)</span> Results are shown in the following graphs for <span class="tex-text">\(D_{ A p}=0.1 \times 10^{-12} m ^{2} / s \text { and } 0.01 \times 10^{-12} m ^{2} / s \text { and for } D_{ As }=0.1 \times 10^{-12} m ^{2} / s , 0.2 \times 10^{-12} m ^{2} / s \text { , and } 0.4 \times 10^{-12} m ^{2} / s\)</span>.</p>
 <p class="blog">
&nbsp;</p>
 <p class="blog">
Note that as either mass diffusivity is increased, the dosage increases.</p>
 <p class="blog">
&nbsp;</p>
 <p class="blog">
<strong>Comments</strong>:<br /> 1. The function of the outer layer of the skin, the epidermis, is to protect the body from external contamination. Transdermal drug delivery is feasible only for medications characterized by extremely small molecules that can diffuse through the relatively<br /> impenetrable epidermis. Mass transfer considerations restrict the number of drugs that can be delivered transdermally.</p>
 <p class="blog">
2. It is desirable to desensitize the dosage to variations in the skin diffusivity, since this parameter varies from patient to patient. Therefore, the host medium of the patch (called the vehicle) is designed so that it is the rate-limiting factor in controlling the dosage. The sensitivity of the dosage to the patient’s skin diffusivity is reduced by decreasing the mass diffusivity in the vehicle, as evident by comparing the results of part 2 of the problem. In general, it is desirable to design the vehicle so that <span class="tex-text">\(D_{ Ap } / D_{ A s} \ll 1.\)</span></p>
 <p class="blog">
3. The patch is designed to deliver medication as though it is a semi-infinite medium. The required patch thickness for this assumption to be valid may be estimated by calculating the location where the density of the medication in the vehicle is reduced to 95% of the difference between <span class="tex-text">\(\rho_{ A , p, i} \text { and } \rho_{ A , p}(x=0)\)</span> over the treatment time. By analogy to Equation 5.60, the concentration penetration depth, <span class="tex-text">\(\delta_{p, c},\)</span> associated with 5% depletion of the drug may be determined from</p>
 <p class="blog">
&nbsp;</p>
 <p class="blog">
<span class="tex-text">\(\frac{T(x, t)-T_{s}}{T_{i}-T_{s}}=\operatorname{erf}\left(\frac{x}{2 \sqrt{\alpha t}}\right)\)</span> (5.60)</p>
 <p class="blog">
&nbsp;</p>
 <span class="tex-text">\(\frac{\rho_{ A , p}\left(x^{\prime}\right)-\rho_{ A , p}\left(x^{\prime}=0\right)}{\rho_{ A , p, i}-\rho_{ A , p}\left(x^{\prime}=0\right)}=0.95=\operatorname{erf} \frac{\delta_{p, c}}{\sqrt{4 D_{ A p} t} t}\)</span> <p class="blog">
&nbsp;</p>
 <p class="blog">
Evaluating this expression yields a species penetration depth of <span class="tex-text">\(690 \times 10^{-6} m = 0.69 mm.\)</span> The assumption of a semi-infinite patch is valid for a vehicle thickness greater than 0.69 mm.</p>
 <p class="blog">
4. If the vehicle is much thinner than the species penetration depth calculated in Comment 3, the actual dosage will fall below the desired dosage prior to the end of the one-week treatment period. Therefore, a tradeoff in the design of the patch involves (a) loading enough medication to ensure semi-infinite behavior and (b) minimizing the cost of the patch. In practice, more than 95% of the medication remains in the vehicle after the treatment period, necessitating careful disposal of the patch after its use.</p>
 
    
          <!-- end -->
            </div>
        </div>
    
    
        <footer class="footer-bg footer-slct">
            <div class="footer-top">
                <a href="/tos">terms</a>
                <a href="/privacy">privacy</a>
                <a href="/contact-us">contact us</a>
            </div>
            <div class="footer-bottom">
                &copy; 2022 Vlavar Inc. All Rights Reserved.
            </div>
        </footer>    
        <script src="https://cdn.jsdelivr.net/npm/katex@0.16.0/dist/katex.min.js" integrity="sha384-X/XCfMm41VSsqRNQgDerQczD69XqmjOOOwYQvr/uuC+j4OPoNhVgjdGFwhvN02Ja" crossorigin="anonymous"></script>
        <script src="https://cdn.jsdelivr.net/npm/katex@0.16.0/dist/contrib/auto-render.min.js" integrity="sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR" crossorigin="anonymous"></script>
        <script src="/assets/js/min/client-ui.js"></script>
    </body>
    
    </html>